Elizabeth (Liz) Tallett
Elizabeth (Liz) Tallett is a respected leader with more than 30 years of experience in the worldwide biopharmaceutical and consumer products industries. Her senior management experience includes President and Chief Executive Officer of Transcell Technologies Inc., President of Centocor Pharmaceuticals, member of the Parke-Davis Executive Committee, and Director of Worldwide Strategic Planning for Warner-Lambert Company. Born and educated in England, she graduated from Nottingham University with dual first class honours degrees in mathematics and economics. Currently, Liz is a Principal of Hunter Partners, LLC, a management consulting practice that provides strategic advice and interim management for early to mid-stage pharmaceutical, biotech and medical device companies. Liz is a member of the board of directors of Principal Financial Group, Inc., Varian, Inc., Coventry Health Care Inc., Meredith Corp. and IntegraMed America Inc. She is currently the Lead Director for both Principal and Coventry Health Care. She was a founding board member of the Biotechnology Council of New Jersey, and is a Trustee of Solebury School, PA.
Paul Blake, MB, F.R.C.P
Dr. Blake is the Chief Medical Officer and Senior Vice President of Clinical Research and Development of Aeterna Zentaris, Inc. Prior to that, he was Senior Vice President and then Executive Vice President of Worldwide Medical and Regulatory Operations at Cephalon, Inc. From 1992 to 1998, he held the position of Senior Vice President and Medical Director, Clinical Research and Development at SmithKline Beecham Pharmaceuticals (now GSK). Prior to that, he worked for ICI Pharmaceuticals (now Astra Zeneca) and G.D. Searle.
He qualified in medicine from the Royal Free Hospital School of Medicine, London University. He is a fellow of the Royal College of Physicians and a fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians. He is also a fellow of the American College of Clinical Pharmacology.
Some of the drugs he was involved in developing include: Tenormin, Zestril, Kytril, Relafen, Paxil, Coreg, Havrix, Hycamtin, Famvir, Requip, Avandia, Provigil and Fentora.
Dr Blake sat on the board of Memory Pharmaceutical, Inc., until it was purchased by Roche in 2009 and was a founding board member of Protez Pharmaceuticals, Inc. until it was purchased by Novartis in 2008. He was also a Director of ViaCell, Inc., until its purchase by Perkin Elmer in 2007. He currently sits on the boards of QR Pharma, Y-Prime and Oxford BioMedica.
He has also served as a member of the Inter-Company Collaboration for AIDS Drug Development and as a trustee of the Children's Health Fund.
Dr. Pusey has more than 25 years of experience in medicine, international clinical trial management, CRO services and global pharmaceutical sales, marketing and operations roles. As one of PharmaVOICE magazine’s Top 100 Most Inspirational Leaders, James is focused on raising investment funds, orchestrating strategic change, and driving growth. James has a track record in a variety of Global Healthcare Sciences organizations.
From 2009 until 2013 James founded the CRO Theorem Clinical Research as a management buy-out from Omnicare Inc. James’ roles included President & CEO, Executive Chairman, and Board Director. Prior to Theorem from 2007 through 2009 Dr Pusey served as SVP and General Manager of Global Clinical Development at MDS Pharma Services. During his tenure James reorganized and restructured this global clinical CRO. The turnaround led to a 2009 EBITDA profit of $11 million resulting in the successful sale of this business to INC.
Other leadership roles include the President & CEO of Orthologic, Inc., a small public biotechnology company based in Phoenix Arizona, Executive Vice President of the Pfizer/Serono joint venture on Multiple Sclerosis from 2003 through 2005 which successfully took the injectable MS treatment Rebif to #1 in North America, and led the team that funded Oral Cladribine Phase III trials to their NDA submission.
Prior to joining Serono, Dr. Pusey served in a variety of roles at AstraZeneca and SmithKline Beecham, and prior to his business career, Dr. Pusey was a practicing physician in the Royal Free and King George Hospitals, St. Bartholomews Hospital and London/Whittington Hospitals, all based in London, UK.